zealand
pharma
grants
warrants
restricted
share
units
employee
warrant
program
management
incentive
program
company
announcement
zealand
pharma
grants
warrants
restricted
share
units
employee
warrant
program
management
incentive
program
copenhagen
september
zealand
pharma
zealand
nasdaq
zeal
announces
granting
warrants
restricted
share
units
rsus
employees
warrants
granted
warrant
program
covered
authority
pursuant
section
zealand
articles
association
adopted
zealand
general
meeting
april
rsus
granted
incentive
program
ltip
zealand
executive
management
corporate
management
accordance
zealand
remuneration
policy
overall
guidelines
incentive
pay
adopted
annual
general
meeting
held
april
grant
warrants
warrant
program
incentive
scheme
reflecting
zealand
objective
attract
retain
employees
help
ensure
shared
interests
management
employees
shareholders
zealand
total
warrants
granted
giving
rights
subscribe
new
zealand
shares
nominal
value
dkk
corresponding
zealand
total
outstanding
share
capital
exercise
price
dkk
calculated
closing
price
zealand
shares
nasdaq
copenhagen
september
warrants
vest
annually
period
exercise
warrants
may
take
place
whole
part
defined
time
windows
september
including
september
exercise
time
windows
defined
four
times
year
window
following
time
publication
either
zealand
annual
report
quarterly
reports
three
six
nine
months
respectively
total
new
warrants
granted
combined
market
value
dkk
million
calculated
basis
model
cost
warrant
dkk
based
parameters
grants
based
average
volatility
average
interest
rate
share
price
dkk
incentive
program
zealand
ltip
intended
drive
performance
align
management
interests
zealand
shareholders
support
attraction
retention
motivation
executive
talent
members
executive
management
corporate
management
eligible
receive
annual
grant
restricted
share
units
rsus
free
charge
rsu
grants
vesting
period
september
september
vested
rsu
entitles
holder
receive
one
share
zealand
cost
provided
holders
continued
employment
throughout
vesting
period
grant
rsus
ltip
estimated
aggregate
theoretical
value
dkk
million
rsu
value
dkk
value
rsus
determined
simple
average
closing
price
zealand
share
nasdaq
copenhagen
period
five
trading
days
prior
grant
date
zealand
pharma
zealand
pharma
nasdaq
zeal
zealand
biotechnology
company
focused
discovery
development
commercialization
innovative
medicines
drug
candidates
invented
zealand
advanced
clinical
development
two
reached
market
zealand
robust
pipeline
investigational
medicines
includes
three
candidates
late
stage
development
one
candidate
reviewed
regulatory
approval
united
states
zealand
markets
insulin
delivery
option
people
diabetes
license
collaborations
boehringer
ingelheim
alexion
pharmaceuticals
create
opportunity
patients
potentially
benefit
peptide
therapeutics
zealand
founded
copenhagen
denmark
presence
throughout
includes
key
locations
new
york
boston
marlborough
information
zealand
business
activities
please
visit
statement
information
contains
statements
provide
zealand
pharma
expectations
forecasts
future
events
statements
subject
risks
uncertainties
inaccurate
assumptions
may
cause
actual
results
differ
materially
expectations
set
forth
herein
may
cause
statements
incorrect
statements
prove
incorrect
actual
results
could
differ
materially
adversely
anticipated
implied
statements
statements
speak
date
release
based
information
available
zealand
pharma
date
release
information
please
contact
mads
kronborg
head
investor
relations
communication
phone
email
mkronborg
media
david
rosen
argot
partners
phone
email
media
